MedTech World to host an Investor-only Forum on Day 0 in Malta 2024
Share Article
Join us for an exclusive Investor-only Forum kicking off MedTech Malta at The Excelsior Hotel on Day 0. This insightful session will feature a panel of seasoned investors who will delve into their backgrounds, discussing their experiences and insights within the medtech industry. Key topics on the agenda include an analysis of the current climate in medtech, what investors are currently seeking in potential opportunities, and the opportune moments for fundraising and fund establishment. Additionally, the panel will explore the mergers and acquisitions landscape in medtech and identify areas where the industry can enhance its practices as well as invite all fellow attendees to pitch in.
“As with CEO-only forums, it’s extremely valuable to maintain focused narratives. The exclusive format allows for in-depth and candid discussions among investors, providing a balanced contrast to broader conferences where interactions span different fields. This setting facilitates the sharing of insights, strategies, and experiences without distractions, creating a conducive environment for building valuable connections and collaborations.”
Cattello Somma, Partner at Seroba.
“We’re thrilled to be hosting the inaugural Investors-Only Forum at MedTech Malta, a significant milestone in our journey at MedTech World. Following the success of last year’s CEO-Only Forum, we expect this event to be equally impactful. This exclusive event is designed to connect visionary investors with pioneering innovations in the medtech sector and offer investors a safe and comfortable environment to discuss any of the challenges they’re facing with fellow peers. I applaud our team for embracing this new challenge within an already busy three-day schedule and and I eagerly anticipate seeing the outcomes of this event.”
Dr. Dylan Attard MD, MRCSI, MEnt, CEO & Co-Founder at MedTech World
In mid-2024, Needham analysts highlighted a downturn in the annual number of medtech acquisitions, projecting the lowest levels since 2017 with 131 deals valued at $32.4 billion. Despite this, they foresee potential for increased merger and acquisition (M&A) activity, buoyed by stabilizing interest rates and attractive valuations of small- and mid-cap companies. However, concerns over antitrust scrutiny under the current administration pose a potential barrier until after the upcoming presidential election. The analysts revised their list of top 25 acquisition targets, adding companies like Neuropace, Zimvie, Artivion, and Masimo while removing Nevro due to its modest growth rate. Recent high-profile acquisitions, such as Shockwave Medical by Johnson & Johnson, underscore the strategic focus on high-growth opportunities and differentiated products in the medtech sector.
In early 2024, PitchBook reported a notable recovery in venture capital funding for medical devices, totaling $3.3 billion in the first quarter, up from $2.8 billion in Q4 2023. This resurgence suggests a potential turnaround for healthcare startups seeking investment, particularly in medtech. If this trend persists, PitchBook anticipates 2024 could see the highest average annual deal value since early 2022. Late-stage investments accounted for nearly half of the funding, highlighted by Freenome’s $254 million raise for cancer detection blood tests. Despite a slow start in exits, including minimal IPOs and acquisitions, Johnson & Johnson’s $13.1 billion acquisition of Shockwave Medical signals optimism for future liquidity events in the sector.
Who else is joining us in Malta?
Thom Rasche, Partner, Earlybird Venture Capital
Tyler Wanke,Investor, Wanke Family Office
Gautam Kainth, Partner, TCP Health Ventures
Catello Somma, Partner at Seroba
John Perez, Managing Director at Rex Health Ventures
Gary Gershony, Founding General Partner at BayMed Venture Partners
Assaf Barnea, Managing Partner at Sanara Capital & Sanara Ventures.
Pablo Prieto, Managing Director at CG Health Ventures
Steven Levy, Partner at Unorthodox Ventures
Joshua Phillips, Managing Partner at Catalyst Health Ventures
Soyoung Park, General Partner, 1004 Venture Partners
and many more.
“The investor-only forum will be an opportunity to engage with other international investors and have focused discussions around themes, trends, and perspectives. My goal is to explore ideas for new investment opportunities, stay updated on the latest industry trends and innovations, and network with experienced investors I can syndicate with”.
Catello went on to say, “Focused gatherings like this forum can bring new ideas and perspectives that will nurture the ecosystem in respective countries. They help investors get an edge on how others think and approach opportunities and investment themes. By fostering a collaborative environment, such forums contribute to the growth and success of the medical device industry as a whole”
Here’s what Konrad Dobschuetz, a German born, dual British national, and a recognised global HealthTech leader had to say when asked on his primary goal for attending the investor-only forum in Malta:
“In my role as a translator of health system needs and solutions, it is very important to understand the market from both sides. Investors have a specific deal flow as well as a forward looking view of the market which needs factoring in when connecting the various players. As an expert in the HealthTech space I would hope to shed some light on some of the needs in the system in terms of real world evidence creation and financial sustainability.”
Konrad Dobschuetz, Founder Director of Leap Advisory & Intelligence
Konrad Dobschuetz, Founder Director of Leap Advisory & Intelligence at MedTech Malta 2024
MedTech Malta is bringing experts together.
Discover MedTech Malta, where medtech and healthtech advancements take centre stage. Join us in Valletta from November 6th to 8th to connect with fellow industry leaders and make the most out of the opportunities we’re curating just for you.
